Recrystallization of fluconazole using the supercritical antisolvent (SAS) process

The supercritical antisolvent (SAS) process was used to modify solid state characteristics of fluconazole. Fluconazole was recrystallized at various temperatures (60–80 °C) and pressures (8–16 MPa) using dichloromethane (DCM) as a solvent. Acetone and ethanol were also employed as solvents. The fluc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2007-01, Vol.328 (2), p.152-160
Hauptverfasser: Park, Hee Jun, Kim, Min-Soo, Lee, Sibeum, Kim, Jeong-Soo, Woo, Jong-Soo, Park, Jeong-Sook, Hwang, Sung-Joo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The supercritical antisolvent (SAS) process was used to modify solid state characteristics of fluconazole. Fluconazole was recrystallized at various temperatures (60–80 °C) and pressures (8–16 MPa) using dichloromethane (DCM) as a solvent. Acetone and ethanol were also employed as solvents. The fluconazole polymorphs prepared by the SAS process were characterized by differential scanning calorimetry (DSC), thermogravimetry analysis (TGA), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM). Furthermore, the equilibrium solubility of the samples in aqueous solution was determined. Fluconazole anhydrate form I was obtained at low temperature (40 °C) and anhydrate form II was obtained at high temperature (80 °C). The variation of pressure during the SAS process may influence the preferred orientation. Anhydrate forms I and II were also obtained using various solvents. Therefore, it was shown that solid state characteristics of fluconazole, including the polymorphic form and preferred orientation, can be controlled by changing operating conditions of the SAS process such as temperature, pressure, and solvent.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2006.08.005